NO991655D0 - FremgangsmÕte for Õ inhibere stress-aktiverte-proteinkinaser - Google Patents

FremgangsmÕte for Õ inhibere stress-aktiverte-proteinkinaser

Info

Publication number
NO991655D0
NO991655D0 NO991655A NO991655A NO991655D0 NO 991655 D0 NO991655 D0 NO 991655D0 NO 991655 A NO991655 A NO 991655A NO 991655 A NO991655 A NO 991655A NO 991655 D0 NO991655 D0 NO 991655D0
Authority
NO
Norway
Prior art keywords
protein kinases
activated protein
inhibiting stress
inhibiting
stress
Prior art date
Application number
NO991655A
Other languages
English (en)
Other versions
NO991655L (no
Inventor
Xinkang Wang
Tian-Li Yue
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Publication of NO991655D0 publication Critical patent/NO991655D0/no
Publication of NO991655L publication Critical patent/NO991655L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
NO991655A 1996-10-09 1999-04-08 FremgangsmÕte for Õ inhibere stress-aktiverte-proteinkinaser NO991655L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2845996P 1996-10-09 1996-10-09
PCT/US1997/018272 WO1998015272A1 (en) 1996-10-09 1997-10-09 Method for inhibiting stress-activated protein kinases

Publications (2)

Publication Number Publication Date
NO991655D0 true NO991655D0 (no) 1999-04-08
NO991655L NO991655L (no) 1999-06-08

Family

ID=21843560

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991655A NO991655L (no) 1996-10-09 1999-04-08 FremgangsmÕte for Õ inhibere stress-aktiverte-proteinkinaser

Country Status (16)

Country Link
US (1) US6214854B1 (no)
EP (1) EP0946172A4 (no)
JP (1) JP2002512591A (no)
KR (1) KR20000048967A (no)
CN (1) CN1157188C (no)
AU (1) AU4751897A (no)
BR (1) BR9712283A (no)
CA (1) CA2267967A1 (no)
CZ (1) CZ123099A3 (no)
IL (1) IL129326A0 (no)
NO (1) NO991655L (no)
NZ (1) NZ335080A (no)
PL (1) PL332638A1 (no)
TR (1) TR199900762T2 (no)
WO (1) WO1998015272A1 (no)
ZA (1) ZA979055B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921773B2 (en) 1999-12-07 2005-07-26 Duke University Use of α-1AR subtype-selective drugs in patients with acute myocardial infarction
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
BR0312102A (pt) * 2002-06-27 2007-05-29 Sb Pharmco Inc sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
EP1539140A4 (en) * 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
CA2540858C (en) 2003-10-14 2009-12-08 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
KR20070085227A (ko) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
WO2015031914A1 (en) * 2013-08-30 2015-03-05 Uti Limited Partnership Store overload-induced calcium release inhibitors and methods for producing and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5405863A (en) 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
US5308862A (en) 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies

Also Published As

Publication number Publication date
EP0946172A1 (en) 1999-10-06
CN1157188C (zh) 2004-07-14
WO1998015272A8 (en) 2000-03-23
PL332638A1 (en) 1999-09-27
AU4751897A (en) 1998-05-05
EP0946172A4 (en) 2002-05-22
ZA979055B (en) 1999-05-10
WO1998015272A1 (en) 1998-04-16
JP2002512591A (ja) 2002-04-23
KR20000048967A (ko) 2000-07-25
CA2267967A1 (en) 1998-04-16
NO991655L (no) 1999-06-08
IL129326A0 (en) 2000-02-17
BR9712283A (pt) 1999-08-31
NZ335080A (en) 2000-04-28
CN1239888A (zh) 1999-12-29
US6214854B1 (en) 2001-04-10
CZ123099A3 (cs) 1999-11-17
TR199900762T2 (xx) 1999-07-21

Similar Documents

Publication Publication Date Title
CY2008015I1 (el) Δικυκλικες ετepοαρωματικες ενωσεις σαν αναστολεις πρωτεϊνης κινασης τυροσινης
DK0806474T3 (da) Fremgangsmåde til at stabilisere drikkevarer
DE69739418D1 (de) System zur Herstimulussteuerung
NO20001748L (no) FremgangsmÕte for Õ modulere serin/treonin proteinkinasefunksjon med 5-azaquinoksalin-baserte forbindelser
NO983405L (no) Fremgangsmåte for ökning av smöreevnen til snöskigrunnflater
NO983892L (no) Inhibitorer for farnesyl-proteintransferase
BR9611724A (pt) Inibidor de quinase c de proteína
PT927183E (pt) Inibidores espirociclicos de metaloproteases
NO20010117D0 (no) Fremgangsmåte for behandling av sövnlöshet
NO991655D0 (no) FremgangsmÕte for Õ inhibere stress-aktiverte-proteinkinaser
ATE205836T1 (de) Bicyclische 4-aralkylaminopyrimidin-derivate als tyrosinkinase-inhibitoren
FI951514A (fi) Uusia mono- ja bisyklisiä DNA-gyraasiinhibiittoreita
DE69700801D1 (de) Verfahren zur Kopositionierung von Satelliten
IS5742A (is) Aðferð til genalækninga
DK0987356T3 (da) Fremgangsmåde til trækning
DE69737237D1 (de) Verfahren zur trockenätzung
ID18300A (id) Metoda penemperan
FI960534A (fi) Menetelmä analyyttien ei-kilpailevaa määritystä varten
DK0912446T3 (da) Fremgangsmåde til behandling af vand
ATE218559T1 (de) Verfahren zur monoacylierung von hydroxytaxanen
UA25728A (uk) Спосіб одержаhhя сорбеhту для очистки меляси
IT1294014B1 (it) Metodo di applicazione per fangoterapia
DK1084215T3 (da) Fremgangsmåde til fraktionering
UA25398A (uk) Спосіб комбіhоваhої холецистолітотомії
UA25135A (uk) Спосіб гастроєюhопластики

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application